Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer

Maurie Markman, MD
Published: Wednesday, Nov 15, 2017



Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Using overall survival (OS) as a primary endpoint for phase III randomized trials is no longer rational, says Markman. This endpoint assumes that what happens to a patient after they go on the trial is going to be similar for patients on either arm of the study.

Therefore, holding a drug or combination “hostage” to an OS endpoint is irrational and risky, explains Markman.


Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Using overall survival (OS) as a primary endpoint for phase III randomized trials is no longer rational, says Markman. This endpoint assumes that what happens to a patient after they go on the trial is going to be similar for patients on either arm of the study.

Therefore, holding a drug or combination “hostage” to an OS endpoint is irrational and risky, explains Markman.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Advent of Oncology Monoclonal Antibody Biosimilars ‒ A European Perspective OnlineNov 30, 20183.0
Publication Bottom Border
Border Publication
x